Therapeutic Serum Range for D-Amphetamine in Children Taking Adderall
There is no established therapeutic serum concentration range for d-amphetamine in children taking Adderall (mixed amphetamine salts). Treatment is guided by clinical response and tolerability, not by blood levels.
Why Serum Monitoring Is Not Used
Dose titration is clinically based: The American Academy of Child and Adolescent Psychiatry guidelines emphasize that amphetamine dosing should be titrated based on symptom improvement and side effect profile, not serum concentrations 1.
No correlation established: Unlike medications such as lithium or valproate, there is no validated therapeutic window for amphetamine blood levels that correlates with clinical efficacy or toxicity in ADHD treatment 2.
High inter-individual variability: Pharmacokinetic studies demonstrate substantial variability in amphetamine metabolism (coefficients of variation 28-56%), making population-based therapeutic ranges impractical 3.
Clinical Dosing Parameters Instead
Since serum levels are not used, treatment relies on:
Starting Doses
- Initial dose: 2.5 mg of dextroamphetamine/mixed amphetamine salts (DEX/AMP) given after breakfast, with a noon dose added if needed 1.
Titration Schedule
- Weekly increases: Dose should be increased by 2.5 to 5 mg increments weekly until symptom control is achieved 1.
- Maximum recommended doses: The Physician's Desk Reference states 40 mg total daily dose for amphetamines, though expert consensus often limits this to 40 mg total daily for children 1.
- Weight-based limits: Children weighing less than 25 kg generally should not receive single doses greater than 10 mg of DEX/AMP 1.
Pharmacokinetic Reference Values (Not Therapeutic Targets)
While not used for clinical decision-making, research provides these pharmacokinetic parameters for reference:
- Time to peak concentration (Tmax): Approximately 3 hours for immediate-release Adderall; 7 hours for extended-release formulations 2, 3.
- Half-life in children aged 6-12: 9 hours for d-amphetamine; 11 hours for l-amphetamine 2.
- Peak concentrations: Highly variable between individuals, ranging from 2645 to 5948 ng/mL in research studies, but these are descriptive values, not therapeutic targets 4.
Monitoring Approach
Clinical assessment replaces serum monitoring 1:
- Obtain ADHD rating scales from parents and teachers at each dose adjustment
- Assess target symptoms weekly during titration
- Monitor for side effects systematically (insomnia, anorexia, headaches, social withdrawal, tics, weight loss)
- Measure vital signs (blood pressure, pulse, height, weight) at baseline and follow-up visits
- Select the dose producing maximum benefit with minimal side effects
Common Pitfall to Avoid
Do not order amphetamine blood levels to guide ADHD treatment—this is not standard practice and provides no clinically useful information for dose adjustment 1, 2. The exception would be suspected toxicity or overdose, where levels might confirm exposure but still would not guide therapeutic dosing.